TrialAntimicrobial agents and chemotherapy2014
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
F Joel Leong et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
31 papers cite it
this papertrialcites it